The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh Investment, Carbonneutral Partnership, and Probe Capital participating.

Enzymaster works with partners in many industries such as pharmaceuticals, food & feed, agrochemicals and flavours & fragrances, where the company’s BioEngine^® Directed Evolution Platform offers innovative, sustainable and economical replacement by engineered enzymes to the classical chemistry routes. According to Dr. Bong Yong Koy, chairman of the board of directors, The core of our company is our proprietary BioEngine^® Directed Evolution Platform, and thus the ability to keep developing synthetic strategies for new products. From the outset, our strategic plan has been to support target industries with a full range of solutions, from enzyme-engineering R&D to commercial-production of chemicals, for facilitating more efficient and sustainable manufacturing, he said. "This round of financing will allow us to continue to advance biomanufacturing innovation as well as further expand our commercial-scale
production capacity".

In addition to the ongoing funding of R&D innovation, Enzymaster acquired Sanming Minhe
Pharmaceutical Technology Co. last November to meet the growing production capacity
demand of customers.The Sanming Minhe acquisition was a critical step toward fulfilling the commercial-scale production needs of the market. We can now produce up to 600 metric tons of enzymes and
chemical compounds utilizing cleaner, greener bio-manufacturing processes., stated Dr. Thomas Daussmann, Enzymaster’s Executive Vice President for International Business. This
round of financing will allow us to continue to invest in the innovation and manufacturing
capacity needed to help transform the global chemical industry.